![January 2023 Labs in Court: Two Usual Cases, Two Unusual Ones](https://www.g2intelligence.com/wp-content/uploads/2022/12/Jan23.LCA_.LabsInCourt-iStock-1800x1250-1-1080x675.jpg)
January 2023 Labs in Court: Two Usual Cases, Two Unusual Ones
Key cases over the last month include a CGx testing kickback scheme, false billing, and violations of a non-compete clause and HIPAA.
Key cases over the last month include a CGx testing kickback scheme, false billing, and violations of a non-compete clause and HIPAA.
Circulating tumor DNA sequencing technologies are tackling the challenges of early cancer detection.
Researchers have identified 35 genes found in high expression in people with long-term Lyme disease, which could lead to earlier detection.
The agency’s latest report to Congress shows that while enforcement activity is returning to pre-pandemic levels, recoveries are still down.
Co-owners sentenced to three years each for paying millions in kickbacks for referrals to their Brooklyn-based facilities.